E-mail Comment Del.icio.us Digg Reddit Technorati Furl

Xenoport Down 64% In Pre-Market Trading

Feb 18, 2010 Uncategorized

Xenoport (XNPT), a biopharmaceutical company, is seeing its shares drop 64.29% in pre-market trading, going from $19.60 to $7.00, after the company announced that a drug that was developed by it and a partner GlaxoSmithKline (GSK) had been denied approval by the Food and Drug administration.

The drug, Horizant, was being developed to treat restless leg syndrome.

Tags: , ,

This entry was posted on Thursday, February 18th, 2010 at 9:10 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.